Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Oncotelic Therapeutics, Inc. | d506519d10k.htm |
| EX-32.1 - EX-32.1 - Oncotelic Therapeutics, Inc. | d506519dex321.htm |
| EX-31.2 - EX-31.2 - Oncotelic Therapeutics, Inc. | d506519dex312.htm |
| EX-31.1 - EX-31.1 - Oncotelic Therapeutics, Inc. | d506519dex311.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| 1. | Registration Statement (Form S-8 Nos. 333-126636, 333-177628, 333-181810 and 333-190409) pertaining to the Mateon Therapeutics, Inc. 2005 Stock Plan, as amended, |
| 2. | Registration Statement (Form S-8 No. 333-159585) pertaining to the Mateon Therapeutics, Inc. 2005 Stock Plan and the Mateon Therapeutics, Inc. 2009 Employee Stock Purchase Plan, and |
| 3. | Registration Statement (Form S-8 No. 333-204500) pertaining to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan |
of our report dated April 17, 2018 (which report expresses an unqualified opinion and includes an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern), with respect to the financial statements of Mateon Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ OUM & CO. LLP
San Francisco, California
April 17, 2018